Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

Mary F. Hebert, Helen E. Smith, Thomas C. Marbury, Suzanne K. Swan, William Smith, Robert W. Townsend, Donald Buell, James Keirns, Ihor Bekersky

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Micafungin is an antifungal agent metabolized by arylsulfatase with secondary metabolism by catechol-O-methyltransferase. The objectives of this study were to estimate the pharmacokinetic parameters and plasma protein binding of micafungin in volunteers with moderate hepatic dysfunction (n = 8), volunteers with creatinine clearance <30 mL/min (n = 9), and matched controls (n = 8 and n = 9, respectively). Single-dose micafungin pharmacokinetics were estimated using noncompartmental techniques. There was a statistically lower area under the observed micafungin concentration-time curve (AUC) from time 0 to infinity for subjects with moderate hepatic dysfunction as compared to control subjects (97.5 ± 19 μg•h/mL vs 125.9 ± 26.4 μg•h/mL, P = .03), although there was no difference in micafungin weight-adjusted clearance (10.9 ± 1.7 mL/h/kg vs 9.8 ± 1.8 mL/h/kg, P = .2). The difference in area under the concentration-time curve may be explained by the differences in body weight between subjects and controls. Renal dysfunction did not alter micafungin pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)1145-1152
Number of pages8
JournalJournal of Clinical Pharmacology
Volume45
Issue number10
DOIs
StatePublished - Oct 1 2005
Externally publishedYes

Fingerprint

Liver Diseases
Volunteers
Healthy Volunteers
Pharmacokinetics
Kidney
Arylsulfatases
Secondary Metabolism
Catechol O-Methyltransferase
Antifungal Agents
Liver
Protein Binding
Area Under Curve
micafungin
Blood Proteins
Creatinine
Body Weight
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. / Hebert, Mary F.; Smith, Helen E.; Marbury, Thomas C.; Swan, Suzanne K.; Smith, William; Townsend, Robert W.; Buell, Donald; Keirns, James; Bekersky, Ihor.

In: Journal of Clinical Pharmacology, Vol. 45, No. 10, 01.10.2005, p. 1145-1152.

Research output: Contribution to journalArticle

Hebert, Mary F. ; Smith, Helen E. ; Marbury, Thomas C. ; Swan, Suzanne K. ; Smith, William ; Townsend, Robert W. ; Buell, Donald ; Keirns, James ; Bekersky, Ihor. / Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. In: Journal of Clinical Pharmacology. 2005 ; Vol. 45, No. 10. pp. 1145-1152.
@article{b2b8fa8d4d804f2d8e12d81f6f163775,
title = "Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction",
abstract = "Micafungin is an antifungal agent metabolized by arylsulfatase with secondary metabolism by catechol-O-methyltransferase. The objectives of this study were to estimate the pharmacokinetic parameters and plasma protein binding of micafungin in volunteers with moderate hepatic dysfunction (n = 8), volunteers with creatinine clearance <30 mL/min (n = 9), and matched controls (n = 8 and n = 9, respectively). Single-dose micafungin pharmacokinetics were estimated using noncompartmental techniques. There was a statistically lower area under the observed micafungin concentration-time curve (AUC) from time 0 to infinity for subjects with moderate hepatic dysfunction as compared to control subjects (97.5 ± 19 μg•h/mL vs 125.9 ± 26.4 μg•h/mL, P = .03), although there was no difference in micafungin weight-adjusted clearance (10.9 ± 1.7 mL/h/kg vs 9.8 ± 1.8 mL/h/kg, P = .2). The difference in area under the concentration-time curve may be explained by the differences in body weight between subjects and controls. Renal dysfunction did not alter micafungin pharmacokinetics.",
author = "Hebert, {Mary F.} and Smith, {Helen E.} and Marbury, {Thomas C.} and Swan, {Suzanne K.} and William Smith and Townsend, {Robert W.} and Donald Buell and James Keirns and Ihor Bekersky",
year = "2005",
month = "10",
day = "1",
doi = "10.1177/0091270005279580",
language = "English (US)",
volume = "45",
pages = "1145--1152",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

AU - Hebert, Mary F.

AU - Smith, Helen E.

AU - Marbury, Thomas C.

AU - Swan, Suzanne K.

AU - Smith, William

AU - Townsend, Robert W.

AU - Buell, Donald

AU - Keirns, James

AU - Bekersky, Ihor

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Micafungin is an antifungal agent metabolized by arylsulfatase with secondary metabolism by catechol-O-methyltransferase. The objectives of this study were to estimate the pharmacokinetic parameters and plasma protein binding of micafungin in volunteers with moderate hepatic dysfunction (n = 8), volunteers with creatinine clearance <30 mL/min (n = 9), and matched controls (n = 8 and n = 9, respectively). Single-dose micafungin pharmacokinetics were estimated using noncompartmental techniques. There was a statistically lower area under the observed micafungin concentration-time curve (AUC) from time 0 to infinity for subjects with moderate hepatic dysfunction as compared to control subjects (97.5 ± 19 μg•h/mL vs 125.9 ± 26.4 μg•h/mL, P = .03), although there was no difference in micafungin weight-adjusted clearance (10.9 ± 1.7 mL/h/kg vs 9.8 ± 1.8 mL/h/kg, P = .2). The difference in area under the concentration-time curve may be explained by the differences in body weight between subjects and controls. Renal dysfunction did not alter micafungin pharmacokinetics.

AB - Micafungin is an antifungal agent metabolized by arylsulfatase with secondary metabolism by catechol-O-methyltransferase. The objectives of this study were to estimate the pharmacokinetic parameters and plasma protein binding of micafungin in volunteers with moderate hepatic dysfunction (n = 8), volunteers with creatinine clearance <30 mL/min (n = 9), and matched controls (n = 8 and n = 9, respectively). Single-dose micafungin pharmacokinetics were estimated using noncompartmental techniques. There was a statistically lower area under the observed micafungin concentration-time curve (AUC) from time 0 to infinity for subjects with moderate hepatic dysfunction as compared to control subjects (97.5 ± 19 μg•h/mL vs 125.9 ± 26.4 μg•h/mL, P = .03), although there was no difference in micafungin weight-adjusted clearance (10.9 ± 1.7 mL/h/kg vs 9.8 ± 1.8 mL/h/kg, P = .2). The difference in area under the concentration-time curve may be explained by the differences in body weight between subjects and controls. Renal dysfunction did not alter micafungin pharmacokinetics.

UR - http://www.scopus.com/inward/record.url?scp=25444513384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444513384&partnerID=8YFLogxK

U2 - 10.1177/0091270005279580

DO - 10.1177/0091270005279580

M3 - Article

VL - 45

SP - 1145

EP - 1152

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 10

ER -